COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD ZincZn
HC Q study #24
Source   PDF   Share   Tweet
See all 155 studies
5/5
Inconc.
Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Gendelman et al., Autoimmunity Reviews, 19:7, July 2020, doi:10.1016/j.autrev.2020.102566 (Peer Reviewed)
Continuous Hydroxych loroquine or Colchicine Therapy Does Not Prevent Infection With SARS-CoV-2: Insights From a Large Healthcare Database Analysis
Very small study of rheumatic disease/autoimmune disorder patients showing no significant difference but with only 3 chronic HC Q patient cases. Only considers people tested at a time when primarily symptomatic cases were tested.
Other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.001 [1], which is the observed real-world risk, taking into account factors such as these patients potentially being more careful to avoid exposure.
Adjusting for the difference in baseline risk using the result in Ferri et al. shows substantial benefit for HC Q, RR 0.211, but with only 3 HC Q cases the result is inconclusive. More recent studies with rheumatic disease/autoimmune condition patients provide higher confidence.
COVID-19 case, ↓8.1%, p=0.88
Source   PDF   Share   Tweet
See all 155 studies
Please send us corrections, updates, or comments.
Submit